PDLIM1P4

Across TCGA pan-cancer cohorts, PDLIM1P4 RNA differs between tumor and matched normal tissue in 10 of 18 cancer types tested, making tumor–normal expression one of PDLIM1P4’s most consistent transcriptional readouts.

The strongest signal is observed in liver hepatocellular carcinoma (LIHC), where PDLIM1P4 RNA is repressed in tumor relative to normal tissue. In most cancer types PDLIM1P4 is over-expressed in tumor, although a few such as LIHC and LUSC show the opposite, repressed pattern.

LIHC, BLCA, and LUSC are the cancer types where PDLIM1P4 tumor–normal differential expression is most reproducible.

RNA tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in PDLIM1P4 RNA (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
LIHC	Female	II,III,IV	−0.605	<.001	8	view →
BLCA	All	All	+0.243	.002	6	view →
LUSC	All	All	−0.364	<.001	5	view →
LUAD	All	II,III,IV	−0.318	.016	4	view →
THCA	Female	All	+0.210	.018	3	view →
KICH	All	All	+0.534	.010	2	view →
KIRP	All	All	−0.241	.007	2	view →
HNSC	Female	All	+0.223	.023	2	view →
BRCA	Female	All	−0.140	.035	2	view →
KIRC	All	All	−0.153	.007	1	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 10 strongest of 10 lineages.

PDLIM1P4–LIHC

Open the LIHC breakdown →